Truist Financial
CRNX icon

Truist Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Truist Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$470K Buy
12,556
+817
+7% +$30.4K ﹤0.01% 2243
2026
Q1 		$426K Buy
11,739
+1,860
+19% +$83.1K ﹤0.01% 2166
2025
Q4 		$460K Buy
+9,879
New +$440K ﹤0.01% 2091

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Truist Financial's CRNX Position: Q2 2026 in Review

Truist Financial increased its Crinetics Pharmaceuticals (CRNX) stake by 7% in Q2 2026, buying an estimated $30.4K and bringing the position to 12,556 shares worth $470K. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

Truist Financial first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Truist Financial held 12,556 shares of Crinetics Pharmaceuticals worth $470K as of Q2 2026.
  • Truist Financial bought 817 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $30.4K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2243 holding.
  • Truist Financial first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.